CXCL12 and acute myeloid leukemia: Based on the promising results in preclinical studies, two cancer targeting aptamers, ACT-GRO-777 (or AS1411) - a G-rich DNA aptamer targeting nucleolin for treatment of acute myeloid leukemia (AML) and NOX-A12 L-RNA aptamer targeting CXCL12 for treatment of multiple myeloma and lymphoma are already in clinical trials [16], [17].